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ENHANCEMENT OF PLATELET RESPONSE TO IMMUNE 
COMPLEXES AND IgG AGGREGATES BY 
LIPID A-RICH BACTERIAL LIPOPOLYSACCHARIDES*$ 
BY M. H. G INSBERG§  AND P. M. HENSON H 
(From the Department oflmmunopathology, Scripps Clinic and Research Foundation, La Jolla, 
California 92037) 
IgG aggregates and immune complexes have been shown to stimulate cells in vitro 
(1-3). This includes the platelet, acell that secretes avariety of constituents in response 
to these stimuli. For example, human platelet secretion is initiated by immune 
complexes and IgG aggregates (1), by aggregated Fcfragments (4, 5) but not aggregated 
F(ab')2 fragments, leading to the concept of a platelet "Fc receptor" (5, 6). This concept 
has recently been strengthened by the demonstration that aggregated IgG binds to 
human platelets and that binding is inhibited more strongly by human IgG than by 
F(ab')2 fragments or bovine IgG (7). The nature of the postulated platelet Fc receptor 
remains unclear, but the fact that the first component ofthe classical complement path- 
way, C1, like the platelet, is activated by aggregated IgG or Fc fragments, has led to the 
hypothesis that C1 bound to the platelet surface plays a critical role in the platelet re- 
sponse to aggregated IgG (8). There is, however, little information on the effects of other 
activators of C1 on platelet function. 
The lipopolysaccharide (LPS) 1 component of gram-negative bacteria is a 
molecule that may be responsible for many of the pathogenic properties of the 
whole organism (9). LPS from smooth bacterial strains consists of a type- 
specific O antigen, a strain-specific core polysaccharide, a trisaccharide of 2- 
keto-3-deoxy octulosonate (KDO), and a lipid termed "lipid A" (10). The KDO- 
lipid A portion of the molecule is remarkably similar in most bacterial strains 
(9) and may be obtained in isolated form as the LPS of heptose-deficient rough 
mutants uch as Salmonella minnesota R595. This lipid-rich LPS and lipid A iso- 
lated by acid hydrolysis of LPS (10) have been shown to provide many of the 
strain independent activities of LPS (11). Both lipid A and lipid A-rich LPS from 
S. minnesota R595 have recently been shown to activate complement via C1 (12, 
* Supported by U. S. Public Health Service grants GMS 19322, A100214-5 (training grant), and 
HL  A17007. 
* A preliminary account of these data appeared in 1977. Fed. Proc. 36:1065a. (Abstr.) This is 
publication no. 1337 of the Department of Immunopathology, Scripps Clinic and Research 
Foundation. 
§ Present address: Department of Pediatrics, National Jewish Hospital, Denver, Colorado 
80218. 
H Recipient of National Institutes of Arthritis, Metabolism, and Digestive Diseases Clinical 
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13). In this paper, we report data showing that lipid A and lipid A-rich LPS 
from S. minnesota R595 (LPS R595) by themselves are not potent platelet 
stimuli. These bacterial products are shown, however, to dramatically poten- 
tiate the effectiveness of IgG aggregates and immune complexes as initiators of 
the platelet release reaction. 
Materials and Methods 
Chemicals. Phenol and chloroform were from Mallinckrodt Inc. (St. Louis, Me.) and the 
petroleum ether (bp = 20-40°C) from J. T. Baker Chemical Co. (Phillipsburg, N. J.). Schwartz 
Mann Div. Becton, Dickinson & Co. (Orangeburg, N. Y.) provided the tris hydroxymethyl amino 
methane (Tris, Ultra Pure) and E. R. Squibb & Sons (Princeton, N. J.) provided the human 
Cohn fraction II (lot no. 2030). The [3H]serotonin binoxalate (1 Ci/mM) in 2% ethanol and the ~31I 
(12-25 Ci/mg) were from New England Nuclear (Boston, Mass.). Bovine serum albumin (BSA; 
was recrystallized three times and was from Armour Pharmaceuticals Company (Phoenix, 
Ariz.). 
Lipopolysaccharide. LPS of S. minnesota R595 was extracted from bacterial paste (New 
England Enzyme Center, Boston, Mass.) by the phenol-chloroform-petroleum ther procedure 
(14). The purified LPS was suspended at a concentration of 2.5 mg/ml in 0.9% NaC1 containing 
0.1% triethylamine, sonicated, and subsequently dialyzed extensively against 0.9% NaC1 to 
remove unbound triethylamine. Lipid A was prepared by acid hydrolysis (15) of Salmonella 
typhimurium R60 LPS and dispersed in 1% triethylamine and dialyzed against 0.9% NaC1. 0.1- 
1% triethylamine alone had no effect on platelet serotonin release in the presence or absence of 
IgG aggregates. 
Gamma Globulin. Purified polyclonal gamma globulin was obtained by diethylamino ethyl 
cellulose chromatography of Cohn fraction II. This material produced a si~gle precipitin arc on 
immunoelectrophoresis at 20 mg/ml when reacted with goat whole anti-human serum. IgG 
myeloma proteins of greater than 95% homogeneity by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis were generously provided by Dr. Hans Spiegelberg of the Scripps Clinic. Pro- 
teins were heat aggregated at 63°C for 30 min at 20 mg]ml in 0.01 M sodium phosphate 0.15 M 
NaCl pH 7. Isolated soluble IgG aggregates were prepared by fractionation of heat-aggregated 
IgG on a 4.5 x 75-cm column containing Ultregel Ac A22 (LKB Instruments, Inc., Rockville, 
Md.). Protein eluting at apparent reel wt of 500,000-1,500,000 daltons was pooled, frozen, and 
stored at -70°C until use. 
Other Platelet Stimuli. Monosodium urate crystals were prepared as described (16). Insoluble 
human skin collagen extracted by the Nishihara procedure was generously provided by Dr. 
George Wilner through Dr. John Griffin of the Scripps Clinic. Crude bovine thrombin was from 
Parke, Davis & Company (Detroit, Mich.). Anti-human platelet antibodies were raised in New 
Zealand white rabbits (Rancho de Conejo, La Jells, Calif.). These antisera were absorbed with 
human red blood cells until they did not agglutinate human neutrophils or red blood cells. In addi- 
tion, no precipitin lines were observed when these antisera were reacted against human plasma 
in immunodiffusion analysis. 
Protein Labeling. IgG was labeled with ~31I by the procedure of McConahey and Dixon (17). 
BSA-Anti-BSA Complexes. Antisera to BSA were raised in New Zealand white rabbits 
(Rancho de Conejo) and contained 417 ~g of antibody nitrogen/ml by quantitative precipitin 
analysis. Immune complexes were precipitated at equivalence using this antiserum and washed 
twice in 0.15 M NaC1 0.01 M sodium phosphate pH 7 before platelet release xperiments. 
Platelet Release Experiments. These were done with plastic apparatus. Blood from normal 
donors who had taken no medication in the previous week was drawn through a 20-gauge needle 
into 1/6 vol acid citrate dextrose (18). Platelet-rich plasma was isolated by centrifugation at 200 g 
in an International centrifuge (International Equipment Co., Boston, Mass.) for 15 rain at room 
temperature and was incubated at 37°C for 30 min with 0.1 ~Ci/ml [3H]seretonin resulting in 
uptake of 80-90% of radioactivity. Platelets were pelleted by centrifugation at 1,000 g for 15 min 
at 10°C in an International centrifuge, and the platelet button resuspended in 30 mM Tris, 120 
mM NaCl, 5 mM glucose (TBS) pH 6.5. The platelets were then recentrifuged and resuspended 
twice before being centrifuged and finally suspended at 2 × 103 ceUs/ml in TBS pH 7.4. These 
suspensions contained less than one white cell per 2,000 platelets. 
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FIG. i. Response of platelets to LPS R595. LPS R595 at the final concentration shown on 
the abscissa was mixed with varying quantities of polyclonal human IgG. Platelet 
suspensions were added and percent serotonin release determined after a 15-rain incubation 
at 37°C. (Preliminary studies had shown a plateau in serotonin release induced by these 
stimuli after a 10-rain incubation). Mean ± SEM of triplicate determinations. Where no 
error bars appear, the error is within the point. 
In general, 100 ~l of test substance was added to 12 x 75-ram Falcon polystyrene (Sherwood 
Medical Industries, Inc., St. Louis, Mo.) tubes and incubated at 37°C for 10 rain, at which time 
400/~l of the prewarmed platelet suspension was added and the mixture incubated with shaking 
at 37°C in a Dubnoff metabolic incubator. At appropriate times, the tubes were placed into ice for 
2-5 rain and centrifuged at 5,000 g for 15 rain at 4°C. To 2 ml of a mixture of equal parts Aquasol 
(New England Nuclear) and toluene, 100 ~l of supernate was added and the mixture counted in a 
Searle Delta 300 liquid scintillation spectrometer (Searle Analytic Inc., Des Plaines, Ill.). 
Percent-spocific release of serotonin was defined as: 
radioactivity in stimulus-treated supornate - 
radioactivity in buffer-troated supernate x 100 
total radioactivity releasable by 0.2% Triton X-100 - 
radioactivity in buffer-treated supernate 
In some experiments, loss of lactic dehydrogenase (LDH) was assayed as well (16). Data were 
analyzed only from those platelet preparations in which less than 10% of total serotonin or LDH 
was in buffer-treated supornates. 
Results 
Effect of LPS R595 and Lipid A on Washed Human Platelets. The ability 
of LPS R595 and lipid A to initiate serotonin secretion from washed human 
platelets was studied. Fig. 1 shows that addition of mixtures of human gamma 
globulin preparations (which induced little serotonin release by themselves) 
and LPS R595 to the cells resulted in significant serotonin release at LPS 
concentrations a  low as 10 ~g/ml. The cytoplasmic enzyme, LDH, was retained 
at all doses of LPS and gamma globulin employed. The LPS alone showed little 
activity at the concentrations tested. Similar data were obtained with platelets 
washed by the techniques of Mustard et al. (19) and Walsh (20). The lipid A 
preparation was comparable to LPS R595 in activity (not shown). 
The gamma globulin preparations may have contained antilipid A antibodies 
(21) which in the presence of lipid A could have formed immune complexes, 
thus leading to the observed platelet stimulation. To explore this possibility, 
the nature of the active material in the gamma globulin preparation was 
studied. 
210 ENHANCEMENT OF PLATELET RESPONSE 
0.3 i 60 
J .2-  40 
~ 30 
2o 1 
g-10 
- -0  
|'0 1'4 i8 
BY LIPOPOLYSACCHARIDES 
Percen t 
$eretenin ~ ~ 
Release 
~4 2'2 
0.D.28 O 
20 3'o 3'4 3'0 4'2 Fraction Number 
FIG. 2. Size of the component of gamma globulin in preparation inducing serotonin 
release in the presence of LPS R595. 10 ml of 20 mg/ml gamma globulin were placed on a 
4.5 x 100-cm column containing Sephadex G200, and 20-ml fractions collected. 100 ~l of each 
fraction was mixed with 50 /~l 500 I~g LPS R595/ml. Percent serotonin release was 
determined 15 min after addition of 350 #al of platelet suspension. Each point is the mean 
of duplicate determinations (© ..... ©, percent serotonin release; $ , ,  absorbance at 280 
rim). 
Size of the Active Material in Gamma Globulin Preparations. When the 
gamma globulin preparations were passed over a Sephadex G200 column 
(Pharmacia Fine Chemicals, Inc., Piscataway, N. J.; Fig. 2), serotonin releasing 
activity in the presence of LPS R595 appeared only in fractions eluting before 
IgG monomer. This suggested that the active material was IgG aggregates ora 
large non-IgG trace contaminant. To help distinguish these possibilities, the 
inactive fraction containing IgG monomer was heated at 63°C. Heating for as 
little as 5 min resulted in serotonin releasing activity when the protein was 
mixed with LPS R595. This suggested that LPS R595 worked to enhance the 
platelet's response to IgG aggregates. The remote possibility that heating 
activated some previously inert contaminant, oraltered antilipid A antibodies, 
still remained. To rule out this possibility, the effect of LPS R595 platelet 
response to heated myeloma proteins was assessed. 
IgG myeloma proteins were heat aggregated at63°C for 30 min. Fig. 3 shows 
that LPS R595 enhanced platelet serotonin release in response to these heat- 
aggregated proteins. This provided strong evidence that LPS R595 or lipid A 
effect on platelets was mediated through IgG. 
Effect of LPS R595 and Lipid A on Platelet Response to IgG 
Aggregates. Because our polyclonal gamma globulin preparations and heated 
myeloma proteins were mixtures of IgG monomer and aggregates, the effects of 
LPS R595 and lipid A on platelet response to purified IgG aggregates were 
quantitated. These results are shown in Fig. 4. LPS R595 or lipid A induced a
50-fold increase in platelet sensitivity to IgG aggregates. 
Effect of Size of IgG Aggregates on Platelet Stimulation in the Presence and 
Absence of LPS. Because IgG aggregates bind to LPS R595 and lipid A, 2 the 
2 M. H. Ginsberg and D. C. Morrison. The binding of aggregated IgG to lipid A-rich bacterial 
lipopolysaccharide. Submitted for publication. 
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FIG. 3. Effect of LPS R595 on platelet response to heat-aggregated myeloma proteins. 50 
~l of 250 ~g/ml LPS R595 or of saline was mixed with 50 ~l of 200 ~g/ml heat-aggregated 
myeloma proteins. Percent serotonin release determined 15 min after addition of 400-~1 
platelet suspension. Mean _ SEM of triplicate determinations. 
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FIG. 4. Effect of LPS R595 and lipid A on platelet response to soluble polyclonal IgG 
aggregates. 50 ~1 of LPS R595 (O O) or lipid A (I------I) at 500 ~g/ml was mixed with 
50 ~l soluble IgG aggregates (final concentration shown on abscissa). Percent serotenin 
release was determined 15 rain after addition of 400-~1 platelet suspension. Mean _+ SEM 
of triplicate determinations. 
possibility arises that this enhancement is due to increased apparent size of 
aggregates in the presence of lipid A. To examine this, the size requirements 
for IgG aggregate-induced platelet stimulation in the presence and absence of 
LPS were studied. To assess these requirements, 131I-IgG was heated at 63°C 
for 30 min and fractionated by gel filtration (Fig. 5) chromatography. Serotonin 
releasing activity was present in fractions larger than IgG monomer and was 
enhanced by the addition of LPS R595. Subsequently, dilutions of fractions corre- 
sponding in size to large (apparent M r >106 daltons-fraction 26) soluble aggre- 
gates, small (apparent M r 3-6 × 105 daltons-fraction 38) soluble aggregates, 
and IgG (fraction 46) monomer were added to platelet suspensions in the pres- 
ence and absence of LPS. Inasmuch as IgG aggregates are unstable, the sizes of 
these three aggregate populations were reassessed on sucrose density gradients 
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Fro .  5. Ge l  filtration of heated gamma globulin. ~3~I-polyclonal g re tna  globulin was 
heated at 20 mg/ml 63°C for 30 rain. 10 ml  was then placed on a 4.5 x 80-cm column 
containing Ultrogel Ac A22 and 20-ml fractions collected. Protein was determined by 
absorbance at 280 nM (0 0) or radioactivity (not shown). 50 kel of each fraction was 
mixed with 50 0.1 0.9% NaC1 (A . . . . .  A) or 250 ~g/ml  LPS  t!595 in saline (© ©), and 
percent serotonin release determined 15 rain after addition of 400-~tl platelet suspension. 
Results are mean of duplicate determinations. 
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FIG. 6. Response of platelets to various sized IgG aggregates. 100/~I of various dilutions 
of IgG fractions (see Fig. 5) were added to 50/~l 0.9% NaCl, and percent serotonin release 
determined 15 rain after addition of 350-/~I platelet suspension. Protein concentrations 
represent the final concentration in the 500-/~I incubation mixture. Results are mean of 
duplicate determinations (O .... O, fraction 26; • 0, fraction 38; • ..... 0, fraction 46). 
at the time they were added to the platelet suspensions. Fig. 6 shows that, in the 
absence of LPS, small soluble IgG aggregates were as effective on a weight 
basis as larger aggregates in stimulating platelets. Fig. 7 indicates that in the 
presence of LPS  R595, the small and large aggregates were again approximately 
equally effective and some 20-fold more active than the same proteins in the 
absence of LPS. Fig. 8 documents the size of the various column fractions, as 
assessed on sucrose density gradients in the absence of LPS, at the same time 
they were added to the platelet suspensions. Because LPS  R595 selectively 
106" 
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FIG. 7. Response of platelets to various sized IgG aggregates in the presence of LPS  
11595. 100 ~l of various dilutions of IgG fractions (see Fig. 5) was added to 50 ~l 250 pg/ml 
LPS R595 in saline, and percent serotonin release determined 15 rain after addition of 350- 
~l platelet suspension. Protein concentrations represent the final concentration in the 500- 
~l mixture. Results are means of duplicate determinations (e .... O, fraction 26; • O, 
fraction 38; • ..... •, fraction 46). 
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FIG. 8. Migration of various sized IgG fractions on sucrose density gradients. 0.4 ml of 
1311-1gG fractions from Fig. 5 was placed on 5-20% linear sucrose gradients at the same 
time the experiments in Figs. 6 and 7 were performed. They were then centrifuged at 
20,000 rpm for 18 h in a SW 50.1 rotor at 4°C. Fractions were collected from the bottom of 
the tube. Greater than 80% of applied radioactivity from each gradient was recovered. 
binds IgG aggregates (see fn. 2), these same fractions were analyzed on sucrose 
gradients in the presence of LPS R595. All of the radioactivity in fraction 26 
was bound by the LPS whereas only 60% of that in fraction 38 and none of that 
in fraction 46 was bound. The unbound material in fraction 38 formed a 
homogeneous 7S peak. Thus, protein concentrations in fraction 38 were cor- 
rected for monomer contamination by multiplying by 0.6. These experiments 
indicate that small and large soluble IgG aggregates are equally effective on a 
weight basis in stimulating the platelet, and their effects are equally enhanced 
by LPS R595. These data suggest that simple increase in the apparent size of 
soluble IgG aggregates is not sufficient to explain enhanced cell stimulation. 
Effect of LPS R595 on Response of Platelets to BSA-Anti-BSA Immune 
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FIG. 9. Effect of LPS R595 on platelet response to BSA-anti BSA immune complexes. 50 
~l of various dilutions of insoluble BSA-anti-BSA immune complexes was mixed with 50 
~l 0.9% NaC1 (© ©) or 250 ~g/~l LPS R595 in 0.9% NaC1 (~-- - -O) .  In addition, 50 ~l 
of dilutions of rabbit gamma globulin plus BSA in 0.9% NaC1 was added to 50 ~l 250 ftg/ml 
LPS R595 ( I  •). Percent serotonin release was determined 15 min a i~r  addition of 
400-pl platelet suspension. Mean _+ SEM of triplicate determinations. 
Complexes. It is possible that LPS R595 acted by effectively insolubilizing 
soluble IgG aggregates. To rule this out, (since immune complexes have similar 
biologic properties to IgG aggregates and are initiators of tissue injury in vivo) 
the effect of LPS on platelet response to insoluble immune complexes was exam- 
ined. Fig. 9 shows the effect of LPS R595 on human platelet secretion induced by 
insoluble rabbit BSA-anti-BSA complexes. The LPS R595 induced a 25-fold en- 
hancement in platelet sensitivity to these immune complexes, but had little 
effect on a mixture of BSA and normal rabbit gamma globulin. 
Effect of LPS R595 on Other Platelet Stimuli. LPS R595 and lipid A 
increased platelet sensitivity to aggregated IgG and immune complexes, leading 
us to examine their effects on other stimuli of platelet secretion. 
Fig. 10 shows that LPS R595 slightly inhibited platelet serotonin release 
induced by a proteolytic enzyme, thrombin, a negatively charged particle, the 
monosodium urate crystal (16), or antiplatelet antibody. The response to 
insoluble human skin collagen was slightly enhanced. In contrast, as before, 
the response to IgG aggregates was markedly enhanced. This indicates that 
LPS R595 does not engender a state of "generalized cellular hypersensitivity" 
and that its effects on platelet stimulation are relatively specific for immune 
complexes. 
Discussion 
The data presented in this report show that the common lipid region of 
bacterial LPS markedly amplifies immune complex-induced platelet serotonin 
release. The release of radioactive serotonin as measured here, reflects the fate 
of the endogenous platelet amine (22). Synergistic release by LPS and aggre- 
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FIG. 10. Effect of LPS R595 on other platelet stimuli. 50 ~1 of a solution containing 500 
pg/ml LPS R595 in 0.9% NaC1 or 0.9% NaCI was added to 50/~1 of various concentrations 
of aggregated IgG, thrombin, insoluble human skin collagen, antiplatelet antibody, or 
monosedium urate crystals in 0.9% NaCI. Percent serotenin release was determined 15 
rain after addition of 400-~1 platelet suspension, mean _+ SEM of triplicate determinations. 
Concentrations indicated are those achieved in the final 500-/~1 incubation mixture 
(O O, stimulus alone; C) O, stimulus + LPS R595). 
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gated IgG probably represents a true secretory reaction as other granule constit- 
uents are released 3 and cytoplasmic LDH is retained under these circumstances. 
IgG monomer  preparations were some 50-fold less active than aggregates in 
inducing platelet serotonin release in the presence of lipid A or LPS R595. This 
may be the result either of minimal serotonin releasing activity on the part of 
IgG monomer, or a 2% contamination (which would not have been detectable 
in our system) of the monomer  preparation with soluble IgG aggregates. 
Heating monomer  to 63°C markedly increased its activity in inducing platelet 
serotonin release, and the activity was associated with aggregate-sized mate- 
rial. Further, heat-aggregated myeloma proteins were active, providing corn- 
polling evidence that the activity of the LPS  was expressed via enhanced 
platelet sensitivity to IgG aggregates, and not through antilipid A antibodies 
or trace contaminants of the protein. 
Aggregated IgG stimulates both platelet (1) and neutrophil (23) secretion. In 
the latter case, small soluble aggregates have been reported to be virtually 
inactive, and this activity is enhanced markedly when the size of the aggregates 
are increased or they are bound to surfaces (23). In contrast to the neutrophil, 
we have shown that platelet secretion is stimulated by very small soluble IgG 
aggregates indicating a difference in the manner in which these cell types 
respond to immune aggregates. The effects of beth large and small IgG 
aggregates and insoluble immune complexes on platelets were enhanced by 
LPS R595. This indicates that although LPS R595 binds immune aggregates, 
the enhancement of cell stimulation is not due to a simple increase in the 
valence of the stimulus as a result of being enlarged or insolubilized. 
The ability of immune aggregates to bind and activate CI and to activate 
3 M. H. Ginsberg and P. M. Henson. Manuscript in preparation. 
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platelets, the inhibition of IgG aggregate-induced platelet stimulation by CI 
(4), and the reported presence of CI activity on washed platelets (8) has led to 
the hypothesis that CI is a platelet immunoglobulin receptor (8). Lipid A or 
LPS R595, potent activators of C~ (12, 13), had little platelet stimulating 
activity themselves. This indicates that a molecule's ability to activate CI does 
not always coincide with the ability to initiate the release reaction of washed 
human platelets. The interaction of platelet-bound C~ with LPS R595 or lipid A 
might have played a role in the enhancement of platelet response to immune 
aggregates, but the data presented here do not permit one to favor this 
possibility above a wealth of others. What is clear is that these two potent 
activators of C1 are not potent platelet stimuli and that IgG4 aggregates, which 
do not activate C~, stimulate the release reaction (4, 5). This implies different 
specificities between the Fc recognition unit of complement, CI, and the 
postulated platelet Fc receptor. 
Bacterial LPS may differ widely in biologic properties. One important 
determinant of these differences is the relative content of lipid A and polysac- 
charide (9). Thus, polysaccharide-rich LPS activates primarily the alternative 
pathway of complement, whereas lipid A-rich LPS activates primarily the clas- 
sical pathway (12, 13). Mueller-Eckhardt and Liischer (24) have reported that 
LPS from Escherichia coli 055:B5 failed to stimulate washed human platelets 
in the presence of a gamma globulin preparation. We have had similar results 
with phenol extracted (15) polysaccharide-rich LPS from E. coli 055:B5. 4 
Because E. coli O55:B5 LPS contains a typical lipid A moiety, these data 
underscore modulation of lipid A effects by the polysaccharide constituent of 
LPS and the importance of using well-characterized LPS preparations in 
defining specific LPS effects. 
LPS is capable of initiating a wide variety of injurious responses in vivo. 
This may be a result of its ability to activate a number of mediation systems. 
Recently, it has become clear that the common lipid region of LPS alone may 
provide the LPS activation signal to many cells, such as murine B cells (25-28) 
and macrophages, ~ and human procoagulant activity generating leukocytes 
(29) and to humoral systems uch as complement via C~ (12, 13). Strikingly, 
immune complexes have important effects on each of these systems as well (3, 
30, 31) and initiate a wide variety of injurious responses invivo. The observation 
that the common lipid A moiety of LPS enhances a cell's response to immune 
complexes may then provide an important clue to the mechanism of the 
multiplicity of LPS effects in vitro and in vivo. 
Summary  
The effect of the common lipid moiety of bacterial LPS on secretion from 
washed human platelets has been studied. The lipid A-rich LPS ofS. minnesota 
R595 and a lipid A preparation beth potentiated platelet serotonin secretion in 
response to IgG aggregates or immune complexes up to 50-fold but had little 
4 M. H. Ginsberg and D. C. Morrison. Manuscript in preparation. 
5 W. F. Doe, S. T. Yang, D. C. Morrison, S. J. Betz, and P. M. Henson. Macrophage 
stimulation by bacterial lipopolysaccharides. If. Evidence for independent stimulation signals 
delivered by lipid A and by a protein-rich fraction of LPS. Submitted for publication. 
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effect in the absence of IgG. Lipid A has been shown to bind immune 
aggregates, raising the possibility that its mechanism of action involved 
effective nlargement or insolubilization of the aggregates. IgG aggregates of
dimer to tetramer size were shown to be platelet stimuli, equivalent on a 
weight basis to larger soluble aggregates. The effect of both sizes of aggregates 
on platelets were equally enhanced by the LPS, indicating that increased size 
of aggregates alone could not account for the effect of LPS. Similarly, because 
lipid A-rich LPS enhanced platelet response to already insoluble immune 
complexes, its mechanism ofaction cannot simply be insolubilization ofimmune 
aggregates. These LPS did not enhance platelet stimulation by antiplatelet 
antibody, monosodium urate crystals, or thrombin and only slightly enhanced 
stimulation by insoluble human skin collagen. This indicates ome stimulus 
specificity in the ability of LPS to increase platelet secretion. The enhancement 
of cell response to immune complexes by the common lipid region of LPS may 
represent a mechanism for the diverse effects of LPS in vivo and in vitro. 
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